Agios Pharmaceuticals, Inc. (AGIO)
USD 30.1
(-2.71%)
USD 30.1
(-2.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.2 Million USD | 69.76% |
| 2022 | -53.6 Million USD | 49.45% |
| 2021 | -106.03 Million USD | -376.83% |
| 2020 | -22.23 Million USD | -167.94% |
| 2019 | 32.73 Million USD | 104.06% |
| 2018 | -805.42 Million USD | -41.86% |
| 2017 | -567.75 Million USD | 1.01% |
| 2016 | -573.56 Million USD | -52.58% |
| 2015 | -375.9 Million USD | -2579.12% |
| 2014 | -14.03 Million USD | 80.39% |
| 2013 | -71.56 Million USD | 21.62% |
| 2012 | -91.29 Million USD | 22.41% |
| 2011 | -117.66 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -50.41 Million USD | -211.04% |
| 2024 Q2 | -19.89 Million USD | 60.53% |
| 2024 Q3 | -192.89 Million USD | -869.42% |
| 2023 Q2 | -5.8 Million USD | 73.36% |
| 2023 Q1 | -21.8 Million USD | 59.33% |
| 2023 FY | -16.2 Million USD | 69.76% |
| 2023 Q4 | -16.2 Million USD | -245.18% |
| 2023 Q3 | 11.16 Million USD | 292.27% |
| 2022 Q4 | -53.6 Million USD | -59.88% |
| 2022 FY | -53.6 Million USD | 49.45% |
| 2022 Q2 | 2.62 Million USD | -81.99% |
| 2022 Q1 | 14.58 Million USD | 113.75% |
| 2022 Q3 | -33.52 Million USD | -1376.66% |
| 2021 Q1 | -1.78 Billion USD | -7924.54% |
| 2021 Q2 | -867.21 Million USD | 51.4% |
| 2021 Q3 | -301.08 Million USD | 65.28% |
| 2021 Q4 | -106.03 Million USD | 64.78% |
| 2021 FY | -106.03 Million USD | -376.83% |
| 2020 Q2 | -186.51 Million USD | -937.88% |
| 2020 Q1 | 22.26 Million USD | -31.99% |
| 2020 Q3 | 2.44 Million USD | 101.31% |
| 2020 FY | -22.23 Million USD | -167.94% |
| 2020 Q4 | -22.23 Million USD | -1009.86% |
| 2019 Q3 | 33.68 Million USD | 2.42% |
| 2019 Q2 | 32.89 Million USD | 216.18% |
| 2019 FY | 32.73 Million USD | 104.06% |
| 2019 Q4 | 32.73 Million USD | -2.83% |
| 2019 Q1 | -28.3 Million USD | 96.49% |
| 2018 Q4 | -805.42 Million USD | -414.72% |
| 2018 FY | -805.42 Million USD | -41.86% |
| 2018 Q3 | -156.47 Million USD | 25.6% |
| 2018 Q2 | -210.32 Million USD | 78.86% |
| 2018 Q1 | -994.74 Million USD | -75.21% |
| 2017 Q1 | -200.27 Million USD | 65.08% |
| 2017 Q2 | -138.71 Million USD | 30.74% |
| 2017 Q3 | -132.74 Million USD | 4.31% |
| 2017 Q4 | -567.75 Million USD | -327.71% |
| 2017 FY | -567.75 Million USD | 1.01% |
| 2016 Q4 | -573.56 Million USD | -100.9% |
| 2016 FY | -573.56 Million USD | -52.58% |
| 2016 Q3 | -285.5 Million USD | 44.27% |
| 2016 Q2 | -512.29 Million USD | -44.0% |
| 2016 Q1 | -355.75 Million USD | 5.36% |
| 2015 FY | -375.9 Million USD | -2579.12% |
| 2015 Q4 | -375.9 Million USD | 7.86% |
| 2015 Q1 | -439.96 Million USD | -3035.66% |
| 2015 Q3 | -407.98 Million USD | 6.0% |
| 2015 Q2 | -434.03 Million USD | 1.35% |
| 2014 Q1 | -32.83 Million USD | 54.11% |
| 2014 FY | -14.03 Million USD | 80.39% |
| 2014 Q4 | -14.03 Million USD | 79.97% |
| 2014 Q3 | -70.04 Million USD | 35.29% |
| 2014 Q2 | -108.24 Million USD | -229.65% |
| 2013 Q1 | -83.37 Million USD | 8.67% |
| 2013 Q2 | -77.48 Million USD | 7.07% |
| 2013 Q4 | -71.56 Million USD | 32.5% |
| 2013 FY | -71.56 Million USD | 21.62% |
| 2013 Q3 | -106.01 Million USD | -36.82% |
| 2012 FY | -91.29 Million USD | 22.41% |
| 2012 Q4 | -91.29 Million USD | 0.0% |
| 2011 FY | -117.66 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Absci Corporation | -72.59 Million USD | 77.673% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 109.861% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.867% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -21416.181% |
| Apollomics, Inc. | -27.39 Million USD | 40.832% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -2371.902% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 81.676% |
| Bicycle Therapeutics plc | -481.46 Million USD | 96.633% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 87.446% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 144.822% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 490.014% |
| Chimerix, Inc. | -25.51 Million USD | 36.478% |
| CRISPR Therapeutics AG | -150.84 Million USD | 89.255% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 109.123% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 94.123% |
| Fortress Biotech, Inc. | 7.66 Million USD | 311.468% |
| Fortress Biotech, Inc. | 7.66 Million USD | 311.468% |
| Gritstone bio, Inc. | 39.49 Million USD | 141.046% |
| Allakos Inc. | -24.97 Million USD | 35.099% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 24.648% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -79.78% |
| Cytokinetics, Incorporated | 642.37 Million USD | 102.523% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 77.407% |
| Innoviva, Inc. | 255.56 Million USD | 106.342% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -75.475% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2302.112% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 60.049% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -188.917% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 79.566% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 57.504% |
| ImmuCell Corporation | 10.99 Million USD | 247.481% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 89.485% |
| Incyte Corporation | -3.17 Billion USD | 99.489% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 201.954% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1264.239% |
| Mustang Bio, Inc. | -3.73 Million USD | -333.86% |
| MiMedx Group, Inc. | -33.9 Million USD | 52.187% |
| MEI Pharma, Inc. | -3.7 Million USD | -337.49% |
| MacroGenics, Inc. | -66.98 Million USD | 75.802% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -123.078% |
| Mereo BioPharma Group plc | -51.46 Million USD | 68.507% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -7.263% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -58.694% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 145.019% |
| Minerva Neurosciences, Inc. | 41 Million USD | 139.53% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 27.092% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -538.652% |
| NextCure, Inc. | -6.47 Million USD | -150.255% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 43.859% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 67.904% |
| Onconetix, Inc. | 5.33 Million USD | 404.027% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -154.099% |
| Opthea Limited | 28.15 Million USD | 157.566% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 185.49% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 335.097% |
| PDS Biotechnology Corporation | -32.7 Million USD | 50.445% |
| Precigen, Inc. | -481 Thousand USD | -3269.854% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 6.823% |
| Prime Medicine, Inc. | -27.94 Million USD | 41.988% |
| PureTech Health plc | -167.19 Million USD | 90.305% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 47.479% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 40.188% |
| Replimune Group, Inc. | 1.41 Million USD | 1247.946% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -35.168% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 158.32% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -599.56% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 97.335% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 12.478% |
| Sesen Bio, Inc. | -112.55 Million USD | 85.599% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -128.296% |
| Solid Biosciences Inc. | -47.75 Million USD | 66.054% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 94.482% |
| SciSparc Ltd. | -2.06 Million USD | -684.939% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 114.283% |
| TG Therapeutics, Inc. | 17.86 Million USD | 190.746% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -7.096% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -161.099% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 104.676% |
| UroGen Pharma Ltd. | 4.39 Million USD | 469.141% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 32.566% |
| XOMA Corporation | -29 Million USD | 44.107% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 191.396% |
| AbCellera Biologics Inc. | -55.94 Million USD | 71.024% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -16.982% |
| Cassava Sciences, Inc. | -121.13 Million USD | 86.619% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 332.618% |
| Precision BioSciences, Inc. | -85.41 Million USD | 81.022% |
| Dyadic International, Inc. | -6.37 Million USD | -154.135% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -93.01% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -1.732% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 46.786% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 51.261% |
| IGM Biosciences, Inc. | -72.6 Million USD | 77.675% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 60.643% |
| Acelyrin, Inc. | -216.9 Million USD | 92.527% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -78.651% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 3.455% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -89.73% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 94.883% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 79.072% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1031.552% |
| Mesoblast Limited | 55.96 Million USD | 128.964% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 35.913% |
| ChromaDex Corporation | -24.04 Million USD | 32.597% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1780.2% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 126.461% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -117.918% |
| Seer, Inc. | -4.24 Million USD | -282.288% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 110.022% |
| Novavax, Inc. | -298.29 Million USD | 94.566% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -77.312% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 126.285% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -228.916% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 80.348% |
| Celcuity Inc. | 6.78 Million USD | 338.947% |
| ContextLogic Inc. | -232 Million USD | 93.013% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 93.312% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 85.336% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.353% |
| Amarin Corporation plc | -191.04 Million USD | 91.515% |
| AnaptysBio, Inc. | -18.15 Million USD | 10.699% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -40.862% |
| Aptorum Group Limited | 1.35 Million USD | 1294.433% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 75.425% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 478.715% |
| Ardelyx, Inc. | 34.51 Million USD | 146.966% |
| Celularity Inc. | 65.19 Million USD | 124.864% |
| Omeros Corporation | 331.17 Million USD | 104.894% |
| Humacyte, Inc. | -22.48 Million USD | 27.915% |
| Immunocore Holdings plc | -358.59 Million USD | 95.48% |
| IO Biotech, Inc. | -140.69 Million USD | 88.48% |
| GT Biopharma, Inc. | -1.02 Million USD | -1487.561% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 91.388% |
| Summit Therapeutics Inc. | 34.67 Million USD | 146.747% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -167.387% |
| Pulmatrix, Inc. | -10.41 Million USD | -55.601% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 85.45% |
| Evogene Ltd. | -19.63 Million USD | 17.444% |
| CorMedix Inc. | -43.05 Million USD | 62.351% |
| BioLineRx Ltd. | 7.33 Million USD | 320.951% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 86.152% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 78.409% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 90.943% |
| scPharmaceuticals Inc. | -6.54 Million USD | -147.655% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -9.951% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 88.029% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2302.112% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 12.478% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 92.213% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 82.526% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 27.275% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 91.22% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 39.199% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 233.262% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 2.895% |
| Daré Bioscience, Inc. | -5.15 Million USD | -214.255% |
| bluebird bio, Inc. | 108.57 Million USD | 114.929% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 104.28% |
| DBV Technologies S.A. | -126.98 Million USD | 87.236% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 90.75% |
| Galecto, Inc. | -21.21 Million USD | 23.6% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -138.263% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 82.33% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 76.087% |
| GlycoMimetics, Inc. | -40.98 Million USD | 60.451% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 113.902% |
| ADMA Biologics, Inc. | 90.06 Million USD | 117.997% |
| Clene Inc. | 3.34 Million USD | 585.299% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 95.29% |
| Aptose Biosciences Inc. | -8.19 Million USD | -97.795% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -418.022% |
| Soligenix, Inc. | -4.95 Million USD | -227.349% |
| Century Therapeutics, Inc. | 847 Thousand USD | 2013.695% |
| Kura Oncology, Inc. | -20.11 Million USD | 19.43% |
| Surrozen, Inc. | -32.66 Million USD | 50.377% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 60.394% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 989.776% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -407.007% |
| Autolus Therapeutics plc | -186.59 Million USD | 91.313% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 67.124% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 147.301% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 31.541% |
| GRI Bio, Inc. | -1.79 Million USD | -803.512% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -80.44% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 403.71% |
| INmune Bio, Inc. | -25.41 Million USD | 36.213% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 110.738% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 68.004% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 0.248% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -74.455% |
| Jaguar Health, Inc. | 29.39 Million USD | 155.15% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -461.851% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 142.638% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 215.113% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 150.836% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 104.289% |
| Verastem, Inc. | -37.27 Million USD | 56.519% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 68.746% |
| Histogen Inc. | -7.48 Million USD | -116.495% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 24.982% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 87.669% |
| Surrozen, Inc. | -32.66 Million USD | 50.377% |
| Organovo Holdings, Inc. | -1.5 Million USD | -975.581% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -285.608% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -93.398% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 62.688% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -11.197% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -2144.827% |
| Kronos Bio, Inc. | -36.05 Million USD | 55.042% |
| Turnstone Biologics Corp. | -14.58 Million USD | -11.142% |
| Synaptogenix, Inc. | -28.66 Million USD | 43.447% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -1631.731% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 2681.051% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 133.262% |
| Exelixis, Inc. | -73.05 Million USD | 77.811% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 32.499% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 93.285% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 80.727% |
| ESSA Pharma Inc. | -33.62 Million USD | 51.79% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -515.811% |
| Avid Bioservices, Inc. | 169.72 Million USD | 109.55% |
| Insmed Incorporated | 721.62 Million USD | 102.246% |
| MediWound Ltd. | -5.32 Million USD | -204.566% |
| OmniAb, Inc. | 9.2 Million USD | 276.127% |
| Alector, Inc. | -35.63 Million USD | 54.516% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 118.854% |
| Zai Lab Limited | -775 Million USD | 97.909% |
| AlloVir, Inc. | -62.69 Million USD | 74.145% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 104.76% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -23.066% |
| Aura Biosciences, Inc. | -21.52 Million USD | 24.697% |
| Immunic, Inc. | -45.34 Million USD | 64.25% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 91.611% |
| Veracyte, Inc. | -203.82 Million USD | 92.048% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 102.539% |
| FibroGen, Inc. | 56.76 Million USD | 128.554% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 282.021% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 87.911% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -473.347% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -682.912% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -385.154% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 90.233% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.033% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 33.765% |
| XBiotech Inc. | -200.02 Million USD | 91.896% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 80.727% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 94.882% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -840.197% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 457.973% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 54.034% |
| Agenus Inc. | 274.13 Million USD | 105.913% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 79.009% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 384.818% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 90.489% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 82.453% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 102.202% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -50.536% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 70.854% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -369.462% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -80.58% |
| Lantern Pharma Inc. | -21.7 Million USD | 25.315% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -283.282% |
| Ainos, Inc. | 4.07 Million USD | 497.481% |
| Pluri Inc. | 22.82 Million USD | 171.002% |
| Prothena Corporation plc | -608.34 Million USD | 97.336% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 86.351% |
| Rallybio Corporation | -24.1 Million USD | 32.748% |
| Kodiak Sciences Inc. | -103.87 Million USD | 84.396% |
| Cue Biopharma, Inc. | -33.81 Million USD | 52.071% |
| MeiraGTx Holdings plc | -40.3 Million USD | 59.781% |
| Annexon, Inc. | -193.75 Million USD | 91.634% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 7.372% |
| Moderna, Inc. | -2.9 Billion USD | 99.442% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 34.043% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 47.545% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.306% |
| Immix Biopharma, Inc. | -17.5 Million USD | 7.429% |
| CalciMedica, Inc. | -5.53 Million USD | -193.11% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 80.248% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 59.515% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 90.365% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 51.256% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -171.19% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 72.96% |
| Nutriband Inc. | -251.65 Thousand USD | -6340.91% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 52.493% |
| Vor Biopharma Inc. | 4.3 Million USD | 476.953% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.731% |
| Alkermes plc | -166.73 Million USD | 90.279% |
| ProKidney Corp. | -56.23 Million USD | 71.177% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 66.697% |
| Arcellx, Inc. | -296.95 Million USD | 94.542% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.188% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 40.983% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 135.125% |
| Atai Life Sciences N.V. | -28.55 Million USD | 43.242% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 826.689% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 28.958% |
| MediciNova, Inc. | -50.78 Million USD | 68.082% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 79.432% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -71956.012% |
| GeoVax Labs, Inc. | -6.45 Million USD | -151.201% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 91.888% |
| Biomea Fusion, Inc. | -166.57 Million USD | 90.269% |
| RenovoRx, Inc. | -1.17 Million USD | -1281.841% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 82.91% |
| Geron Corporation | 14.76 Million USD | 209.81% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 454.993% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 93.086% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 82.795% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 83.062% |
| Royalty Pharma plc | 5.65 Billion USD | 100.286% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 58.516% |
| Imunon, Inc. | -4.21 Million USD | -284.66% |
| BioAtla, Inc. | -109.01 Million USD | 85.131% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 235.459% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 23.553% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 88.482% |
| Structure Therapeutics Inc. | -124.33 Million USD | 86.964% |
| 89bio, Inc. | -289.05 Million USD | 94.392% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 2.12% |
| aTyr Pharma, Inc. | -7.44 Million USD | -117.6% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 86.995% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 80.18% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -1786.557% |
| Akari Therapeutics, Plc | -3.84 Million USD | -321.56% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1098.774% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.174% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 119.389% |
| Liquidia Corporation | -80.17 Million USD | 79.783% |
| Entera Bio Ltd. | -10.62 Million USD | -52.498% |
| GH Research PLC | -78.07 Million USD | 79.24% |
| Vericel Corporation | 1.27 Million USD | 1369.303% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 7.715% |
| Xencor, Inc. | 29.64 Million USD | 154.679% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -722.87% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 0.248% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -6518.404% |
| Vaxcyte, Inc. | -368.22 Million USD | 95.598% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 88.232% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 87.178% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1264.239% |
| Portage Biotech Inc. | -4.98 Million USD | -225.417% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -71956.012% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 75.486% |
| OncoCyte Corporation | -6.56 Million USD | -146.975% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 1906.192% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -255.8% |
| Purple Biotech Ltd. | -14.13 Million USD | -14.648% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 12.709% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -176.604% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 72.444% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 31.769% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 29.452% |
| United Therapeutics Corporation | -507.7 Million USD | 96.807% |
| HilleVax, Inc. | -165.48 Million USD | 90.205% |
| Silo Pharma, Inc. | -3.52 Million USD | -359.92% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 16346.529% |
| Pharming Group N.V. | 109.8 Million USD | 114.762% |
| Tharimmune, Inc. | -10.93 Million USD | -48.226% |
| Genprex, Inc. | -6.73 Million USD | -140.574% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 86.061% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 95.605% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 258.99% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1056.959% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -388.672% |
| OKYO Pharma Limited | -826.84 Thousand USD | -1860.336% |
| Savara Inc. | 153 Thousand USD | 10694.118% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 229.558% |
| Curis, Inc. | -23.88 Million USD | 32.143% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -1988.756% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 1467.848% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.281% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 91.266% |
| Erasca, Inc. | -37.21 Million USD | 56.446% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1158.567% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1158.567% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -56.578% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -49.144% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 48.331% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 49.774% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 52.848% |
| Adicet Bio, Inc. | -138.78 Million USD | 88.321% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 108.184% |
| Aditxt, Inc. | 18.12 Million USD | 189.449% |
| Adagene Inc. | -87.62 Million USD | 81.502% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -289.132% |
| Quantum-Si incorporated | -118.55 Million USD | 86.328% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -116.866% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 66.586% |
| Compugen Ltd. | -12.9 Million USD | -25.612% |
| Generation Bio Co. | 31.44 Million USD | 151.542% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 90.757% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 47.583% |
| Invivyd, Inc. | -198.47 Million USD | 91.833% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 82.044% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -576.026% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 77.103% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -137.495% |
| 2seventy bio, Inc. | 181.71 Million USD | 108.92% |
| Instil Bio, Inc. | 75.35 Million USD | 121.509% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -78.46% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -420.126% |
| GeoVax Labs, Inc. | -6.45 Million USD | -151.201% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 37.657% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -296.156% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -211.173% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 87.561% |
| Evaxion Biotech A/S | 5.28 Million USD | 406.591% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 85.601% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 87.652% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 68.532% |
| Cingulate Inc. | 3.08 Million USD | 625.808% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -451.89% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 325.532% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 84.642% |
| Clearmind Medicine Inc. | -3.94 Million USD | -311.121% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 272.271% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1211.632% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 70.125% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 193.813% |
| ImmunityBio, Inc. | 618.22 Million USD | 102.622% |
| Korro Bio, Inc. | -132.94 Million USD | 87.808% |
| Kineta, Inc. | -4.54 Million USD | -256.948% |
| BioVie Inc. | -17.73 Million USD | 8.591% |
| Codexis, Inc. | -43.27 Million USD | 62.541% |
| Celularity Inc. | 65.19 Million USD | 124.864% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 121.869% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -411.486% |
| Virax Biolabs Group Limited | -3.36 Million USD | -381.702% |
| Cibus, Inc. | -8.07 Million USD | -100.656% |
| IN8bio, Inc. | -16.38 Million USD | 1.098% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 45125.0% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -361.401% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.537% |
| Eyenovia, Inc. | 1.25 Million USD | 1387.755% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 160.245% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -399.815% |
| Elevation Oncology, Inc. | -19.11 Million USD | 15.216% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 51.247% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 16.902% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 72.469% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 21.798% |
| Moolec Science SA | 117.61 Thousand USD | 13881.288% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 57.788% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 57.252% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 88.538% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 27.944% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -131.908% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -202.246% |
| Humacyte, Inc. | -22.48 Million USD | 27.915% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 35.786% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -809.086% |
| Genelux Corporation | -6.89 Million USD | -134.947% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 47.812% |
| Notable Labs, Ltd. | -9.77 Million USD | -65.804% |
| Immunovant, Inc. | -635.22 Million USD | 97.448% |
| Quantum-Si incorporated | -118.55 Million USD | 86.328% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -291.238% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 301.931% |
| Acasti Pharma Inc. | -23 Million USD | 29.541% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -381.375% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 90.425% |
| PepGen Inc. | -60.67 Million USD | 73.283% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 15.251% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1780.2% |
| Immuneering Corporation | -54.94 Million USD | 70.498% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -285.608% |
| Belite Bio, Inc | -87.27 Million USD | 81.427% |
| XOMA Corporation | -29 Million USD | 44.107% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 77.073% |
| Bionomics Limited | 227 Million USD | 107.14% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -539.913% |
| uniQure N.V. | -102.95 Million USD | 84.256% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -289.132% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 139.581% |
| Forte Biosciences, Inc. | -11.96 Million USD | -35.515% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -423.851% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 15391.509% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -399.815% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 282.021% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -118.568% |
| Altimmune, Inc. | -134.48 Million USD | 87.948% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 91.262% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -539.913% |
| Peak Bio, Inc. | 10.34 Million USD | 256.758% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -5627.562% |
| Benitec Biopharma Inc. | -50.58 Million USD | 67.955% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 84.465% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 182.51% |
| Zura Bio Limited | -99.8 Million USD | 83.759% |
| PolyPid Ltd. | 6.17 Million USD | 362.707% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 182.51% |
| argenx SE | -2.02 Billion USD | 99.201% |
| Immunome, Inc. | -97.02 Million USD | 83.295% |
| Verona Pharma plc | -220.44 Million USD | 92.647% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 77.407% |
| Shattuck Labs, Inc. | -121.42 Million USD | 86.651% |
| CervoMed Inc. | -7.79 Million USD | -107.998% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -270.661% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 87.696% |
| Moolec Science SA | 117.61 Thousand USD | 13881.288% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -608.442% |
| Design Therapeutics, Inc. | -18.15 Million USD | 10.694% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 76.97% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 244.311% |
| Achilles Therapeutics plc | -126.92 Million USD | 87.229% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1211.632% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -117.863% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 104.765% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 168.292% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 96.378% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 88.448% |
| Beam Therapeutics Inc. | -262.72 Million USD | 93.83% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 174.299% |
| AEON Biopharma, Inc. | -4.88 Million USD | -232.152% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 70.985% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 83.768% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -590.393% |
| NeurAxis, Inc. | 145.7 Thousand USD | 11224.914% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 58.466% |
| Lumos Pharma, Inc. | -28.49 Million USD | 43.112% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 21.974% |
| Palisade Bio, Inc. | -12.06 Million USD | -34.37% |
| Nutriband Inc. | -251.65 Thousand USD | -6340.91% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 80.537% |
| Neurogene Inc. | -131.95 Million USD | 87.716% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -230.189% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 95.703% |
| Athira Pharma, Inc. | -88.99 Million USD | 81.787% |
| HCW Biologics Inc. | 2.85 Million USD | 667.408% |
| XOMA Corporation | -29 Million USD | 44.107% |
| Nektar Therapeutics | 210.24 Million USD | 107.71% |
| Arvinas, Inc. | -313.8 Million USD | 94.835% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1098.774% |
| Merus N.V. | -192.88 Million USD | 91.597% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 127.022% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -133.626% |
| Rezolute, Inc. | -68.16 Million USD | 76.222% |
| Clene Inc. | 3.34 Million USD | 585.299% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -22.917% |
| BeyondSpring Inc. | -13.75 Million USD | -17.841% |
| Synlogic, Inc. | -6.68 Million USD | -142.468% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 1529.365% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -91.709% |
| Peak Bio, Inc. | 10.34 Million USD | 256.758% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 80.334% |
| Krystal Biotech, Inc. | -350.23 Million USD | 95.372% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 113.059% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 90.409% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -413.407% |
| MannKind Corporation | 143.89 Million USD | 111.264% |
| Ikena Oncology, Inc. | -109.15 Million USD | 85.151% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -114.093% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 51.03% |
| Gossamer Bio, Inc. | 180.35 Million USD | 108.987% |
| CohBar, Inc. | -5.93 Million USD | -173.305% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 45.512% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 454.993% |
| Legend Biotech Corporation | -949.39 Million USD | 98.293% |
| Mural Oncology plc | -255.84 Million USD | 93.664% |
| Disc Medicine, Inc. | -358.28 Million USD | 95.476% |
| Champions Oncology, Inc. | 4.81 Million USD | 436.845% |
| REGENXBIO Inc. | 54.76 Million USD | 129.596% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -5927.734% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 89.267% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -79.86% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 79.91% |
| Vaxart, Inc. | -8.24 Million USD | -96.687% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 67.698% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 87.254% |
| Cellectis S.A. | -43.85 Million USD | 63.04% |
| Longeveron Inc. | -2.9 Million USD | -457.393% |
| Repare Therapeutics Inc. | -107.85 Million USD | 84.972% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.674% |
| Inozyme Pharma, Inc. | 12 Million USD | 235.03% |
| Revolution Medicines, Inc. | -608.2 Million USD | 97.335% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -1217.805% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 93.886% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 89.199% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -3.592% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -2090.405% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.831% |
| Denali Therapeutics Inc. | -74.86 Million USD | 78.349% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -35.168% |
| Veru Inc. | 4.77 Million USD | 439.103% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -44.131% |
| Cingulate Inc. | 3.08 Million USD | 625.808% |
| Passage Bio, Inc. | 4.58 Million USD | 453.522% |
| Context Therapeutics Inc. | -14.44 Million USD | -12.174% |
| Exicure, Inc. | 5.84 Million USD | 377.124% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 92.964% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 59.037% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 203.301% |
| Nuvalent, Inc. | -335.38 Million USD | 95.167% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1034.591% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 78.238% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -82.328% |
| OmniAb, Inc. | 9.2 Million USD | 276.127% |
| Anew Medical, Inc. | 1.43 Million USD | 1231.546% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 198.945% |
| Lipocine Inc. | -4.75 Million USD | -240.913% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 85.241% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 206.421% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 68.004% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 165.117% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -141.169% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 75.376% |
| Ocugen, Inc. | -32.52 Million USD | 50.158% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 81.059% |
| Q32 Bio Inc. | -37.94 Million USD | 57.286% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -2481.051% |
| Alumis Inc. Common Stock | -13.52 Million USD | -19.809% |
| Equillium, Inc. | -22.39 Million USD | 27.613% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 36.604% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 50.32% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -6438.128% |
| Dominari Holdings Inc. | 195 Thousand USD | 8412.308% |
| Edesa Biotech, Inc. | -5.26 Million USD | -207.752% |
| vTv Therapeutics Inc. | -8.91 Million USD | -81.776% |
| Bio-Techne Corporation | 267.74 Million USD | 106.054% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 86.274% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -92.895% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -28.124% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 93.387% |
| Nkarta, Inc. | 57.29 Million USD | 128.288% |
| BioCardia, Inc. | 212 Thousand USD | 7745.755% |
| Iterum Therapeutics plc | 13.43 Million USD | 220.621% |